10 results about "Lethal dose" patented technology

This invention belongs to the field of radiation mutagenesis technology, and relates to a method for mutagenesis of lavender seeds, employing... 60 Lavender seeds are treated with Co-γ rays; the radiation dose is 50-500 Gy, and the dose rate is 1-3 Gy / min. This invention employs... 60 Radiation with Co-γ rays can efficiently induce mutations in the genetic material of lavender seeds, effectively breaking gene linkage and significantly increasing the mutation frequency. This provides a rich material basis for screening lavender mutants, allowing for the selection of seed half-lethal doses, and obtaining plants with variations in leaf color, leaf shape, plant height, and other traits. This provides technical support for lavender breeding using radiation mutagenesis technology.

The invention relates to the technical field of drug side reaction risk prediction, in particular to a tumor patient drug side reaction risk prediction system based on multi-source data. The system comprises a data acquisition module used for integrating multi-source time series data, including medication dosage, pharmacokinetic parameters and clinical index changes, and constructing a multi-dimensional data set; the cumulative effect analysis module is used for calculating a drug attenuation factor, a binding dose and median lethal dose quantitative cumulative effect intensity based on first-order elimination kinetics, and capturing drug metabolic dynamics; due to the fact that the interaction influence effect possibly exists between the drugs, the influence coefficient analysis module is used for adopting elastic network regression and analyzing the drug main effect and the drug combination interaction effect, and determining the main influence coefficient and the interaction influence coefficient of the drugs on each clinical index; and the risk prediction module is used for weighting and optimizing decision tree sorting through the abnormal contribution degree, and outputting the risk probability of each side reaction in combination with a random forest algorithm.

The invention provides a schizothorax fish fertilized egg ultraviolet radiation damage experiment device and method. The device comprises a life support system, a main experiment system, a water inlet and outlet system and an oxygen supply system. The top of the main experimental system is divided into four independent areas, a metal net bag is hung in each area through a fixing device, stable water flow is formed at the 45-degree inclination angle of the tail end of a water inlet pipe, and the life support system maintains the water temperature to be 13-18 DEG C and the water quality to be stable. The method comprises the following steps: acquiring ultraviolet data in a natural reproduction period, setting intensity (low / medium / high) and time (short / medium / long) gradients, irradiating fertilized eggs from P1 to P7 periods, counting a death rate and analyzing a semi-lethal dose. Water environment interference is eliminated through integrated design, an accurate and efficient ultraviolet radiation injury experiment is achieved, and the device is suitable for schizothorax fish fertilized egg protection research. Water environment interference is eliminated through integrated design, an accurate and efficient ultraviolet radiation injury experiment is achieved, and the device is suitable for schizothorax fish fertilized egg protection research.

The present application relates to the technical field of drug side reaction risk prediction, and particularly relates to a tumor patient drug side reaction risk prediction system based on multi-source data. The system comprises: a data acquisition module for integrating multi-source time series data, including drug dosage, pharmacokinetic parameters and clinical index changes, and constructing a multi-dimensional data set; a cumulative effect analysis module for calculating a drug attenuation factor based on first-order elimination kinetics, quantifying the cumulative effect intensity in combination with the dosage and median lethal dose, and capturing the drug metabolism dynamics; since there may be interactive effects between drugs, an influence coefficient analysis module is used to analyze the drug main effect and the joint drug interaction effect by using elastic network regression, and to determine the main influence coefficient and the interaction influence coefficient of the drug on each clinical index; a risk prediction module for optimizing the decision tree sorting by the abnormal contribution degree weighting, and outputting the risk probability of each side reaction in combination with the random forest algorithm.

The invention discloses a calcium ion binding protein marker combination for evaluating individual radiosensitivity and application of the calcium ion binding protein marker combination, and belongs to the technical field of biotechnology and nuclear radiation protection. Aiming at the technical problems that a genomics detection method and a functional experiment method for evaluating individual radiosensitivity have obvious limitation and the like at present, the invention is based on a C57BL / 6J mouse half lethal dose radiation experiment for the first time; a radiosensitivity prediction model based on the serum calcium ion binding protein combination (Ihh, NUCB1 and PROS1) is screened and established through a high-throughput mass spectrometry technology, and the clinical application value of the serum calcium ion binding protein combination (Ihh, NUCB1 and PROS1) as the radiosensitivity prediction marker is proved for the first time. A novel molecular marker is provided for professional radiation protection monitoring and formulation of a precise tumor radiotherapy scheme.

The invention discloses a pharmaceutical composition for preventing and treating acute radiation sickness and application thereof. Animal experiments prove that the combined use of the estrogen anti-release drug and the thrombopoiesis promoting drug can obviously improve the survival rate of animals irradiated by lethal and even super lethal dose, can obviously increase the proportion and absolute quantity of hematopoietic stem cells and progenitor cells in bone marrow of the irradiated animals, and enhances the extramedullary hematopoietic activity of the spleen at the same time; and the recovery of hematopoietic functions of leukocytes, platelets and erythrocytes is promoted. According to the invention, the treatment effect on acute radiation sickness is remarkably improved by combining the estrogen drugs and the thrombopoiesis promoting drugs, and a new treatment scheme is provided for prevention and treatment of acute radiation sickness.

The invention discloses application of combination of dimethyl sulfoxide and thrombopoiesis promoting drugs in treatment of acute radiation sickness. It is found for the first time that a combined scheme of DMSO and thrombopoiesis promoting drugs can significantly improve the survival rate of animals irradiated by lethal and even super lethal dose, animal weight reduction caused by radiation is reversed, and a significant synergistic effect is shown. The invention provides a safe and reliable radiation prevention and treatment measure for patients suffering from acute high-dose radiation exposure, and has a wide clinical application scene.

The invention discloses an apolipoprotein marker combination for evaluating individual radiosensitivity and application thereof, and belongs to the technical field of biotechnology and nuclear radiation protection. Aiming at the technical problems that a genomics detection method and a functional experiment method for evaluating individual radiosensitivity have obvious limitations and the like at present, the invention screens and establishes a radiosensitivity prediction model based on serum apolipoprotein combinations (APOA1, APOA2 and APOA4) through a high-throughput mass spectrometry technology on the basis of a C57BL / 6J mouse half lethal dose radiation experiment for the first time; the clinical application value of the apolipoprotein combinations (APOA1, APOA2 and APOA4) as the radiosensitivity prediction marker is confirmed for the first time, and a novel molecular marker is provided for professional radiation protection monitoring and formulation of a precise tumor radiotherapy scheme.

The invention discloses an application of combination of an estrogen drug and DMSO in preparation of a drug for resisting radiation damage. It is found for the first time that combined administration of estrogen drugs and DMSO can significantly improve the survival rate of animals irradiated by a lethal dose and reverse animal weight loss caused by radiation, and a significant synergistic effect is shown; meanwhile, the ratio and the absolute quantity of hematopoietic stem cells and progenitor cells in bone marrow can be remarkably increased through combined medication of the hematopoietic stem cells and the progenitor cells, the extramedullary hematopoietic activity of the spleen is enhanced, and recovery of hematopoietic functions of leukocytes, platelets and The invention provides a new thought and direction for the field of radiation damage.

This invention discloses the application of hemp seed oil in the preparation of drugs for the prevention or mitigation of acute ionizing radiation-induced diseases, relating to the field of biomedical technology. This invention discovers that hemp seed oil can protect the intestinal epithelium and crypt structures under acute high-dose irradiation, maintaining the intestinal barrier and digestive function. Simultaneously, it can protect splenic immune function by slowing the reduction in the white pulp region of the spleen and increasing the number of nucleated cells and lymphoid immune cells in the spleen, thereby significantly improving the individual survival rate after lethal doses of radiation, providing a new approach for treating acute ionizing radiation-induced diseases.